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a b s t r a c t
We conducted a pilot study evaluating double umbilical cord blood transplantation (dCBT) after myeloa-
blative conditioning with ﬂudarabine and busulfan 3.2 mg/kg i.v.  4, followed by total lymphoid irradiation
at 400 cGy (FluBu4/TLI) for any indicated hematological disorder for patients without a suitable donor.
Twenty patients with predominantly high-risk disease underwent dCBT according to protocol. The regimen
was well tolerated, with mucositis as the primary observed toxicity (n ¼ 19). The cumulative incidence of
neutrophil engraftment was 89% (95% conﬁdence interval [CI], 64% to 97%), with a median time to recovery of
16 days (range, 12 to 31 days). All evaluable patients with neutrophil engraftment achieved complete donor
chimerism by day 40. The cumulative incidence of grades III and IV acute graft-versus-host disease (GVHD) at
day 100 was 10% (95% CI, 2% to 27%), and the cumulative incidence of chronic GVHD was 35% (95% CI, 16% to
55%) by the end of the study. At 1 year, the cumulative incidence of treatment-related mortality (TRM) was
35% (95% CI, 16% to 55%). The leading cause of nonrelapse mortality was acute GVHD (n ¼ 4), followed by graft
failure (n ¼ 2) and chronic GVHD (n ¼ 1). TRM was signiﬁcantly associated with a pretransplantation
hematopoietic cell transplantationespeciﬁc comorbidity index score  3 (P ¼ .005). At 1 year, disease relapse
occurred in 6 patients and overall survival was 40% (95% CI, 19% to 60%). We conclude that FluBu4/TLI is an
adequate preparative regiment before dCBT, providing high engraftment rates and relatively early neutrophil
recovery. The best survival outcomes were seen in patients without signiﬁcant comorbidities before trans-
plantation, and outcomes are comparable to previously published dCBT studies.
 2014 Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.
INTRODUCTION
Umbilical cord blood (UCB) has become an increasingly
utilized alternative cell source for hematopoietic stem cell
transplantation. Less stringent criteria for HLA matching
allows for greater access to suitable units, and a suitable UCB
unit can be made available in days [1,2]. In adults and larger
children, single-unit UCB transplantation has been linked to
slower neutrophil recovery and higher likelihood of graft
failure because of low cell dose [3-6]. To overcome single-
UCB cell dose limitations, a double-unit umbilical cord
blood transplantation (dCBT) strategy was introduced and
successfully validated in several adult studies [7-9].
At this time, the optimal myeloablative conditioning
regimen before dCBT in regards to engraftment, treatment-
related mortality (TRM), or prevention of relapse remains
unknown. Most successful trials to date have utilized total
body irradiation (TBI)ebased myeloablative conditioning
regimens in combination with cyclophosphamide and/or
ﬂudarabine [10-12]. Although these regimens may exert a
potent antitumor effect and sufﬁcient immunosuppression to
facilitate mismatched unrelated cord blood engraftment, the
toxicity with this approach may be contributing to the overall
increased TRM seen with dCBT. Fludarabine and busulfan
3.2 mg/kg i.v  4 (FluBu4) is a widely used myeloablative
regimen for bone marrow and peripheral hematopoietic stem
cell transplantation, with favorable tolerability and lower
TRM, compared with other myeloablative regimens [13-15].
Experience with FluBu4 in the setting of UCB transplantation
is limited. In a previous study (Duke, MD Anderson Cancer
Center) where FluBu4 was utilized, engraftment was low
[15,16]. To augment immunosuppressionwithout signiﬁcantly
adding toxicity, we conducted a pilot study to assess the safety
and efﬁcacy of performing dCBT using FluBu4 followed by
low-dose total lymphoid irradiation (TLI) at 400 cGy (FluBu4/
TLI) as our preparative regimen.
PATIENTS AND METHODS
Study Design
This was a pilot study conducted at the University of Michigan Health
Systemwith institutional review board approval. The primary objective was
to estimate the 1-year survival rate for patients receiving dCBT using a
conditioning regimen of FluBu4/TLI. Our initial target sample size was 30
subjects, set for feasibility. Stopping rules in this study were graft failure
>10% at 35 days and all-cause mortality >50% at 100 days. These conditions
were not met during our study. Between October 2008 and February 2012, a
total of 21 consecutive patients were eligible and enrolled. All patients
signed informed consent according to institutional guidelines. The median
follow-up for survivors was 2.65 years (range, 1.63 to 4.36 years).
Patient Selection
Patients from 0 to 65 years of age, with a diagnosis of an incurable
malignant or nonmalignant hematological disorder, with no suitable
matched related or unrelated donor were eligible for the study. Patients
with acute myelogenous leukemia (AML) or acute lymphoblastic leukemia
could not have >10% blasts in their pretransplantation bone marrow. In
patients with AML or myelodysplastic syndrome (MDS), there could not be
any evidence of ﬁbrosis of the marrow. Before transplantation, patients with
non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia had to be
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in at least partial remission and patients with multiple myeloma (MM) had
to be in at least a very good partial response.
Other routine transplantation eligibility criteria included performance
status using Karnofsky or Lanksy criteria of 70% or higher, no signiﬁcant
medical comorbidities/conditions, negative serologies for hepatitis B, hep-
atitis C, and human immunodeﬁciency virus, and no uncontrolled infection.
Finally, patients were required to have 2 partially HLA-matched UCB
units, with a minimum 4/6 HLA match between UCB units and patient, and
3/6 match between UCB units. One unit must have been able to deliver a
precryopreserved total nucleated cell dose of at least 2.5  107 per kilogram
and the second unit, at least 2  107 per kilogram.
Treatment Plan
All patients received ﬂudarabine 40 mg/m2 i.v. over 30 minutes daily for
4 days and each dose was immediately followed by busulfan 3.2 mg/kg i.v.
over 4 hours for 4 days (days 5 to 2). Busulfan kinetics were performed
on all patients to achieve a steady-state concentration of 600 to 900 mg/mL.
TLI at 400 cGy was performed in 1 session on day -1 or day 0. No antithy-
mocyte globulin (ATG) was given. All patients then underwent dCBT on day
0 and the UCB units were administered sequentially.
Supportive Care
All supportive care measures followed institutional clinical practice
guidelines. Levetiracetam 1000 mg twice daily was given 12 hours before
and for 48 hours after i.v. busulfan administration for seizure prophylaxis.
Granulocyte colony-stimulating factor was given beginning on day þ1 at
a dose of 5 mg/kg daily until the absolute neutrophil count (ANC)was>2500/
mL for 2 consecutive days or >5000/mL for 1 day.
Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus
and mycophenolate mofetil. Tacrolimus was begun on day -3 and was
adjusted tomaintain awhole blood trough level of 8 to 12 ng/mL. Tacrolimus
was given to at least day þ180 without evidence of GVHD. Mycophenolate
mofetil was begun on day 0 at 15 mg/kg/dose every 12 hours and was
continued until day þ28 with neutrophil engraftment and without GVHD.
HLA Typing and Chimerism Analysis
HLA typing was done with combined HLA class I (A, B, and C)
intermediate-resolution, and class II (DR, DQ) high-resolution tests. Bone
marrow or blood was collected after transplantation for donor chimerism
assay studies on days þ30, þ60, þ100, þ180, and þ365. Chimerism was
determined by comparative analysis of donor and recipient microsatellite
markers, utilizing multiplex polymerase chain reaction and differential
ﬂuorescence analysis. The threshold for detection of residual recipient cells
was 5% of all nucleated cells.
Clinical Variables
At time of data analysis, each patient’s pretransplantation comorbidities
were reviewed and scored using the hematopoietic cell transplant-speciﬁc
comorbidity index (HCT-CI) [17]. Additionally, each patient’s pre-
transplantation disease characteristics were reviewed, and patients were
assigned a disease risk score of low, intermediate, or high, using a previously
validated disease risk index scale [18].
Engraftment was deﬁned by the ﬁrst of 3 consecutive days with an ANC
500/mL. Failure to achieve an ANC >500/mL within 35 days of stem cell
infusionwas deﬁned as primary engraftment failure. Platelet engraftmentwas
deﬁned by the ﬁrst of 7 consecutive days with a platelet count 20,000/mL
without transfusion support. One patient with biopsy-conﬁrmed leukemic
relapse on day 15 was excluded from engraftment analysis.
History and physical examinations were performed on days þ30, þ60,
þ100, þ180, and þ365 and as clinically indicated to assess for GVHD.
Acute and chronic GVHD were diagnosed and scored using previously
established criteria [19,20].
Overall survival (OS) was calculated from the day of transplantation, and
TRM was deﬁned as death from any cause other than relapse. Event-free
survival (EFS) was calculated from day of transplantation until relapse or
death.
Statistical Analyses
OS and EFS were estimated using standard Kaplan-Meier methods, and
asymptotic 95% conﬁdence intervals (CI) were generated based on Green-
wood’s variance formula. Secondary outcomes include neutrophil engraft-
ment, platelet engraftment, acute GVHD (aGVHD), and chronic GVHD
(cGVHD), estimated using cumulative incidence estimates, with death and
relapse as competing risks. Additionally, an estimate of TRM was made
based on cumulative incidence estimates, with relapse as a competing risk.
Comparisons of time-to-event curves between subgroups were performed
using the log-rank test. A Cox proportional hazard model was used to assess
joint effects of signiﬁcant covariates. All statistical work was performed
using Stata 12.1 (StataCorp, College Station, TX).
RESULTS
Patient Characteristics
A total of 21 patients were enrolled between October
2008 and February 2012; 20 underwent UCB transplantation
according to protocol, and 1 did not because of disease
progression. Patient characteristics are summarized in
Table 1. The majority were male (55%, n ¼ 11); median age
was 49 (range, 13 to 64 years) and median weight was 85 kg
(range, 40 to 135 kg) at time of transplantation.
AML was the predominant diagnosis (45%, n ¼ 9), most
with high-risk cytogenetics (n ¼ 6), followed by NHL (n ¼ 5).
The remaining diagnoses included MDS (n ¼ 3), acute
lymphoblastic leukemia in early relapse (n ¼ 1), MM (n ¼ 1),
and acquired aplastic anemia (n¼ 1). Overall disease risk was
low in 2 patients (10%), intermediate in 8 patients (40%), and
high in 10 patients (50%).
The median number of total nucleated cells (TNC) infused
was 5.32  107/kg (range, 4 to 15.6) of actual recipient body
weight. The median number of TNCs in the larger UCB unit
was 3.94  107/kg (range, 2.1 to 4.4). HLA matching between
recipient and donor and between donor units are described
in Table 1.
Engraftment and Chimerism
The cumulative incidence of neutrophil engraftment was
89% (95% CI, 64% to 97%), with a median time to recovery of
16 days (range, 12 to 31 days). The cumulative incidence of
platelet engraftment was 73% (95% CI, 48% to 88%), with a
Table 1
Patient and Graft Characteristics
Patient and Graft Characteristics Value
No. of Patients 20
Age, median (range), yr 49 (13-64)
Sex
Male 11 (55%)
Female 9 (45%)
Weight, median (range), kg 85 (40-135)
CMV-positive recipients 11 (55%)
Disease diagnosis
AML 9 (45%)
CR1, n 4
CR2, n 5
MDS 3 (15%)
RA, n 2
CMML, n 1
NHL 5 (25%)
ALL, early relapse 1 (5%)
Aplastic anemia 1 (5%)
MM, CR2 1 (5%)
Pretransplantation disease risk
Low 2 (10%)
Intermediate 8 (40%)
High 10 (50%)
Total cell dose, median (range), TNC  107/kg* 5.32 (4-15.6)
Recipient-graft HLA matching
5/6 þ 5/6 3 (15%)
4/6 þ 5/6 8 (40%)
4/6 þ 4/6 9 (45%)
Graft-graft HLA matching
3/6 11 (55%)
4/6 5 (25%)
5/6 4 (20%)
CR1 indicates ﬁrst complete remission; CR2, second complete remission;
RA, refractory anemia; CMML, chronic myelomonocytic leukemia; ALL,
acute lymphoblastic leukemia.
Data presented are n (%) unless otherwise indicated.
* Total cell dose represents cell dose before thawing for transplantation.
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median time to recovery of 43 days (range, 26 to 86 days).
Figure 1 illustrates these results.
Two patients (10%) failed to engraft by day 35 and expe-
rienced primary graft failure. Before transplantation, 1 had a
diagnosis of aplastic anemia; the second patient had MDS.
The ﬁrst patient demonstrated absence of chimerism on day
28 bone marrow biopsy, and the second patient had a day 30
bone marrow biopsy with donor chimerism and ﬁndings
suggestive of hemophagocytic lymphohistiocytosis. These 2
patients died within 80 days of transplantation.
Patients were evaluated for donor chimerism if they
achieved neutrophil engraftment and were in remission at
time of evaluation. All evaluable patients achieved complete
donor chimerism on bone marrow chimerism studies per-
formed on day 30, and this persisted at day 100. Single donor
dominancewas also seen in all but 1 patient on bonemarrow
chimerism studies at day 30 and day 100. Peripheral blood
chimerism studies on days 30, 60, 100, 180, and 365 revealed
complete donor chimerism in all patients, and single donor
dominance in all but 1 case. In the majority of patients
(n ¼ 12, 71%), the dominant cord blood graft was that with
the higher TNC. However, cell dose was not statistically
associated with engraftment.
GVHD
The cumulative incidences of grade II to IV and grade III
and IV aGVHD at day 100 was 40% (95% CI, 19% to 60%) and
10% (95% CI, 2% to 27%), respectively (Figure 2). Sites affected
by aGVHD included the skin, gastrointestinal tract, and liver.
By the end of the study, 6 patients developed cGVHD and the
cumulative incidence of cGVHDwas 35% (95% CI, 16% to 65%).
Onset was de novo in 4 patients, quiescent in 2 patients, and
progressive in 1 patient. Using National Institutes of Health
criteria, 4 patients had mild cGVHD, 2 patients had moderate
cGVHD, and 1 patient had severe cGVHD [20]. Sites affected
by cGVHD included the skin, mouth, eyes, lungs, and kidney.
Infection
Within the ﬁrst 100 days, 27 documented infections
occurred in 16 patients. Bacterial infections included
coagulase-negative Staphylococcus bacteremia (n ¼ 2),
vancomycin-resistant Enterococcus bacteremia (n ¼ 1),
Escherichia coli bacteremia (n¼ 1), Achromobacter baumannii
bacteremia (n ¼ 1), and Pseudomonas species pneumonia
(n ¼ 1). Nine patients developed human herpes viruse6
viremia, 5 developed BK virus cystitis, 1 had human
metapneumovirus pneumonia, and 3 developed cytomega-
lovirus (CMV) viremia. Three patients receiving high-dose
corticosteroids for treatment for aGVHD died of infection as
a secondary cause of death.
Transplantation Outcomes
At day 100 and at 1 year, the cumulative incidence of TRM
was 25% (95% CI, 9% to 45%) and 35% (95% CI, 16% to 55%),
respectively. TRM was not associated with CMV status
(P¼ .07) or disease risk (P¼ .69). Univariate analysis revealed
that TRM was signiﬁcantly associated with a pre-
transplantation HCT-CI score 3 (P ¼ .005). Five patients had
an HCT-CI score  3. The 1-year TRM in this subgroup was
estimated at 89% (95% CI, 49% to 99%). In comparison, 15
patients had an HCT-CI score <3, and 1-year TRM in this
subgroup was estimated at 23% (95% CI, 8% to 56%). Univar-
iate analysis also revealed that TRM was signiﬁcantly
associated with age 50 years (P ¼ .04). On multivariate
analysis, including CMV status, HCT-CI score, and age 50 as
variables, the strongest predictor of TRMwas an HCT-CI score
3 (P¼ .05). These patients were 5 times as likely to die from
nonrelapse causes (hazard ratio, 5.6; 95% CI, 1 to 32). On
multivariate analysis, age was not a signiﬁcant predictor of
TRM.
With a median follow-up of 2.65 years among survivors,
disease relapse was observed in 6 patients (30%). By disease
state, relapse occurred in 4 patients with AML demonstrating
high-risk cytogenetic features before transplantation, 1 pa-
tient with NHL who underwent transplantation in complete
remission (CR) after failed autologous transplantation, and 1
patient with MMwho underwent transplantation in CR after
failed autologous transplantation. Relapse occurred in 0 of 2
patients with low-risk disease, 2 of 8 patients with
intermediate-risk disease, and 4 of 10 patients with high-risk
disease before transplantation; however, the difference in
relapse rate between these groups was not statistically sig-
niﬁcant (P ¼ .65).
Estimated OS at 1 year was 40% (95% CI, 19% to 60%), and 7
(35%) patients are in continuous CR with a median follow-up
of 2.35 years after transplantation (range, 1.32 to 4.36 years)
(Figure 3). The EFS at the end of this study was 35% (95% CI,
16% to 55%). EFS was not signiﬁcantly associated with disease
risk, age  50, or HCT-CI score 3. The main cause of death
outside relapse was GVHD. Four patients died during
Figure 2. Cumulative incidence of grade II to IV and grade III to IV acute
GVHD.
Figure 1. Cumulative incidence plots for neutrophil and platelet engraftment.
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treatment of aGVHD and 1 patient died from cGVHD. Graft
failure accounted for 2 deaths.
DISCUSSION
DCBTextends access to transplantation for adolescents and
adultswithout anavailable relatedorunrelateddonor. TheEFS
and OS after dCBT in adults are comparable to related and
unrelated donor transplantations for a variety of malignant
and nonmalignant hematological conditions [7-10,21]. Previ-
ously reported successful myeloablative conditioning regi-
mens for dCBT include cyclophosphamide (120 mg/kg), TBI
(13.2 Gy) with ﬂudarabine (75mg/m2), and TBI (13.5 Gy) with
ﬂudarabine (160mg/m2) [10-12]. Given the high engraftment
rates and low TRM seen with myeloablative FluBu4 in the
setting of related or unrelated donor transplantation, we
assessed whether performing dCBT using FluBu4 followed by
TLI at 400 cGy would achieve similar results. In our study, we
report favorable engraftment and toxicities using FluBu4/TLI.
Moreover, despite treatingahigh-risk population in this study,
a sizable number of patients enjoy a prolonged EFS and OS.
The cumulative incidence of neutrophil engraftment in
our study was 89%, consistent with previously reported
values of 80% to 91% [10-12]. Further, compared with the low
engraftment rates reported utilizing FluBu4 for dCBT (Duke,
MDAnderson Cancer Center), the addition of TLI has resulted
in excellent engraftment [15,16]. Finally, we observed rela-
tively rapid engraftment at a median of 16 days. Delayed
engraftment has been associated with decreased survival in
dCBT. In a study comparing dCBT with related and unrelated
peripheral blood stem cell transplantation, Brunstein et al.
noted patients who received a dCBT had an increase in
nonrelapse mortality compared with those with other donor
sources, and the strongest factor implicated was delayed
neutrophil recovery, especially if recovery was delayed
beyond 26 days after transplantation [8]. In our study, only 3
of 17 had neutrophil recovery later than 26 days and the
latest neutrophil recovery occurred was 31 days.
We decided to utilize TLI in this study, and we omitted
ATG because of the adverse effects of ATG, including delayed
immune reconstitution. Our study was not designed to
quantify immune reconstitution; however, we did not
experience any deaths primarily due to infection and we
experienced a low relapse rate. Of note, our total infused cell
dose (median, 5.32  107/kg; range, 4 to 9.6  107/kg) was
higher than in previous studies and may have contributed to
better engraftment rates, as well. Although we did experi-
ence high engraftment, we also had 2 cases of graft failure.
Two cases are too few to analyze; however, 1 graft failure
occurred in a patient with aplastic anemia, which is known
to be less likely to engraft [22].
At the end of our study, with amedian observation time of
2.35 years after transplantation, the estimated OS was 35%.
Themajority of deaths (n¼ 6, 30%)were secondary to relapse,
reﬂecting the large proportion of patients with high-risk
disease. Our overall TRM of 35% was not different from pre-
viously published experience using standard myeloablative
conditioning [10-12]. On the other hand, our TRM among
patients with an HCT-CI score of 3 or more was high at 89%.
Healthier patients, regardless of age, appeared to fare better
with a TRM of 23%. The rates of both aGVHD and cGVHDwere
comparablewith other dCBTstudies and lower than expected
in mismatched unrelated transplantation from other sources
[8]. Only 10% of patients developed grade III and IV aGVHD,
and 30% developed cGVHD by the end of this study.
In summary, our study suggests FluBu4/TLI is an adequate
preparative regiment before dCBT, providing high engraft-
ment rates and relatively early neutrophil recovery.
Compared with FluBu4 alone, the addition of TLI at 400 cGy
may have contributed to improved engraftment. Although
larger studies in a randomized control setting are required to
accurately compare different myeloablative regimens, our
outcomes appear in line with previous successful dCBT trials.
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a b s t r a c t
Improving outcomes among class 3 thalassemia patients receiving allogeneic hematopoietic stem cell trans-
plantations (HSCT) remains a challenge. Before HSCT, patients whowere 7 years old and had a liver size 5 cm
constitute what the Center for International Blood and Marrow Transplant Research deﬁned as a very higherisk
subset of a conventional high-risk class 3 group (here referred to as class 3 HR).We performedHSCT in 98 patients
with related and unrelated donor stem cells. Seventy-six of the patients with age < 10 years received the more
conventional myeloablative conditioning (MAC) regimen (cyclophosphamide, busulfan,  ﬂudarabine); the
remaining 22 patients with age  10 years and hepatomegaly (class 3 HR), and in several instances additional
comorbidity problems, underwent HSCT with a novel reduced-toxicity conditioning (RTC) regimen (ﬂudarabine
and busulfan). We then compared the outcomes between these 2 groups (MAC versus RTC). Event-free survival
(86% versus 90%) and overall survival (95% versus 90%) were not signiﬁcantly different between the respective
groups; however, there was a higher incidence of serious treatment-related complications in the MAC group, and
althoughwe experienced 6 graft failures in theMAC group (8%), therewere none in the RTC group. Based on these
results,we suggest that (1) class 3HR thalassemia patients can safely receiveHSCTwith our novel RTC regimenand
achieve the same excellent outcome as low/standard-risk thalassemia patients who received the standard MAC
regimen, and further, (2) that thisnovelRTCapproach shouldbe tested in the low/standard-riskpatientpopulation.
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INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the only curative treatment for thalassemia
patients [1]. A myeloablative conditioning regimen (MAC) of
busulfan (Bu) followed by 4 days of cyclophosphamide (Cy)
(BuCy4) has, for several years, been considered the standard
of care for HSCT in severe thalassemias [2]. The outcome of
HSCT is dependent on patients’ pretransplantation risk
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